Alivus Life Sciences to Attend Multiple Investor/Analyst Meets in February 2026
Alivus Life Sciences Limited will attend three investor and analyst meetings in February 2026. These include the MANTHAN conference on Feb 10, Nuvama conference on Feb 11, and Kotak conference on Feb 26, all in Mumbai. Meetings will be in-person and in group/one-on-one formats.
This is a standard disclosure regarding participation in investor events and does not contain any material financial information or strategic decisions that would significantly impact the company's stock.
The announcement is an intimation of upcoming investor meetings, which is a routine disclosure and does not inherently contain positive or negative news.
Alivus Life Sciences Limited, formerly Glenmark Life Sciences Limited, has announced its participation in several investor and analyst meetings scheduled for February 2026. These meetings are intended to provide updates and engage with the investment community.
The company representatives will attend the MANTHAN - Systematix India Annual Conference in Mumbai on February 10, 2026. Subsequently, they will participate in the Nuvama India Conference 2026, also in Mumbai, on February 11, 2026.
The series of meetings will conclude with the Kotak Conference - CHASING GROWTH 2026, taking place in Mumbai on February 26, 2026. All these meetings are scheduled to be held in-person and will be conducted in a group or one-on-one format. The company has noted that the schedule and mode of these meetings may be subject to change due to unforeseen circumstances.
What to do with a filing like this
Alivus Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under investor meet intimation. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alivus Life Sciences Limited. Read the original for the full detail.